Bristol-Myers Squibb Will Buy Mega-Biotech Celgene For $74 Billion In Cash And Stock

Analysts are calling it “a big win” for Celgene shareholders.

Read the full post on Forbes - Healthcare

Ellie Kincaid, Forbes Staff